Information About Molnupiravir ▼
The information on this page is intended for UK Healthcare Professionals only
Reporting of suspected adverse reactions
Adverse events should be reported. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000).
This link will take you to a third-party website. MSD do not review or control the content of any third-party site. We do not endorse and are not responsible for the accuracy, content, practices or standards of any third-party sources.
Electronic Medicines Compendium: Summary of Product Characteristics and Patient Information Leaflet
For scientific, medical or product quality enquiries about MSD products please contact:
Phone: 0208 1548000
The MHRA has issued a Conditional Marketing Authorisation for Lagevrio (molnupiravir) in Great Britain and a temporary Regulation 174 authorisation for Northern Ireland to ensure supply across all of the UK.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://coronavirus- yellowcard.mhra.gov.uk for how to report side effects.
GB-ANV-00002 | Date of Preparation: November 2021